Why the study?
The prevalence, clinical profile, management, and 1-year outcomes of patients with LVSD identified through routine TTE in tertiary care needed evaluation, along with a risk stratification tool to identify those requiring specialized HF care referral.
Population
483 consecutive adults with LVEF <= 40% identified among 12,205 subjects undergoing TTE in 2021
Comparison
HF Clinic vs General Cardiologists vs Non-cardiologists follow-up
Design
Single-center retrospective cohort study
Follow-up
12 months
Answers are grounded in this paper and cite their sources.
Cardiology follow-up may lower death or hospitalization risk; leaves open whether routine referral improves outcomes in similar patients.
Background/Objectives: To evaluate the prevalence, clinical profile, management, and 1-year outcomes of patients with left ventricular systolic dysfunction (LVSD) identified through routine transthoracic echocardiography (TTE) in a tertiary care setting, and to develop a tool that stratifies the risk of death or hospitalization and thereby helps identify patients who require referral to specialized heart failure (HF) care. Methods: Single-center, retrospective cohort study of consecutive adults with a left ventricular ejection fraction (LVEF) ≤ 40% identified by TTE in 2021. According to the follow-up received during the subsequent year, patients were classified into three groups: “HF Clinic” (56.9%), “General Cardiologists” (23.0%), or “Non-cardiologists” (20.1%). The primary outcome was the composite rate of all-cause death or hospitalization at 12 months. A multivariable logistic regression model was used to derive the PROACTIVE-HF risk score, internally validated by bootstrap. Landmark analyses at 30 and 90 days and a time-dependent Cox model were performed to address potential immortal time bias related to follow-up classification. Results: Of 12,205 subjects who underwent TTE, 506 had LVSD (4.15% of patients undergoing TTE); 483 formed the final cohort. Patients followed by Non-cardiologists were older, more comorbid, and received less guideline-directed medical therapy. The primary endpoint occurred in 40.4% of the global cohort and was markedly higher in the Non-cardiologists group compared with General Cardiologists and HF Clinic groups (72.2% vs. 34.2% vs. 31.6%, p < 0.001), mainly driven by higher all-cause death (57.7% vs. 10.8% vs. 7.6%, p < 0.001). Most deaths in the Non-cardiologists group were non-cardiovascular. In the time-dependent model, cardiology follow-up was associated with a lower hazard of the primary endpoint (hazard ratio 0.42, 95% confidence interval 0.30–0.59). The PROACTIVE-HF score (age, body mass index [BMI], diabetes mellitus, use of sodium–glucose cotransporter-2 [SGLT2] inhibitors, loop diuretics, renin–angiotensin–aldosterone system [RAAS] inhibitors, and TTE referral by non-cardiologists) discriminated low- (16.8%), intermediate- (37.9%), and high-risk (66.5%) groups for the 1-year primary endpoint (C-statistic 0.75; 0.73 after bootstrap optimism correction). Conclusions: A significant gap exists in the referral pathways for patients with LVSD identified by routine TTE. Patients without cardiology follow-up had worse 1-year outcomes; this association persisted after accounting for immortal time bias, but likely reflects, in part, frailty and competing non-cardiac illness. The PROACTIVE-HF score offers a pragmatic triage strategy that may facilitate more equitable access to specialized HF care, pending external validation.
No takes yet. Share an insight, caveat, or question.
Rueda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: